Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Operating Expenses (2022 - 2025)

Historic Operating Expenses for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $85.7 million.

  • ARS Pharmaceuticals' Operating Expenses rose 25981.27% to $85.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.6 million, marking a year-over-year increase of 27029.2%. This contributed to the annual value of $92.2 million for FY2024, which is 3653.89% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Operating Expenses stood at $85.7 million, which was up 25981.27% from $63.3 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Operating Expenses peaked at $85.7 million during Q3 2025, and registered a low of $6.8 million during Q2 2022.
  • Moreover, its 4-year median value for Operating Expenses was $18.0 million (2023), whereas its average is $26.1 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 3378.23% in 2023, then soared by 29981.69% in 2025.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' Operating Expenses stood at $15.4 million in 2022, then plummeted by 33.78% to $10.2 million in 2023, then soared by 285.14% to $39.4 million in 2024, then skyrocketed by 117.58% to $85.7 million in 2025.
  • Its last three reported values are $85.7 million in Q3 2025, $63.3 million for Q2 2025, and $45.2 million during Q1 2025.